Recent Updates
Recently added Catalysts
XLO Positive Sentiment

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Monday, March 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xilio Therapeutics announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled for March 9, 2026. The company's management will engage in a fireside chat, which will be accessible via a live webcast. Xilio is dedicated to developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes.
Price reaction · baseline $7.3962 (2026-02-27 close) · hit pre-market · clean, no other XLO news in the window
day 0 close · peak
+2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xilio Therapeutics is actively engaging with investors at a major healthcare conference.
  • The company is focused on innovative immuno-oncology therapies.
  • The webcast allows broader access to their developments and insights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website atir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visitingwww.xiliotx.comand follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor ContactAlex Lobo, Precision AQalex.lobo@precisionaq.com

Media ContactJosie Butler, 1ABjosie@1abmedia.com

Frequently Asked Questions

When is Xilio Therapeutics presenting at the conference?

Xilio Therapeutics will present on March 9, 2026, at 3:00 p.m. ET.

How can I access the live webcast?

The live webcast can be accessed on the Xilio Therapeutics website under 'Events & Presentations'.

What is the focus of Xilio Therapeutics?

Xilio Therapeutics focuses on developing masked immuno-oncology therapies for cancer treatment.

Will the webcast be available after the event?

Yes, a replay of the webcast will be available for 30 days post-presentation.

ShareAdd on Google
Tags: XLO Viatris Investor Conferences Healthcare Xilio Therapeutics Leerink Partners immuno-oncology cancer therapies biotechnology
Last updated: Mar 2, 2026

Biotech snapshot

Cash runway
$136M liquidity · $6M/mo burn
~22 mo
Low dilution risk
Lead asset
XTX501Phase 1
Metastatic NSCLC - Non-Small Cell Lung Cancer →

Catalyst track record

+66%
best trade around XLO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XLO.

See every catalyst's timing & PoA →